The science of epigenetics will get a $95 million boost from a new collaboration between Constellation Pharmaceuticals Inc. and Roche Group. The two companies will launch a sweeping three-year collaboration to seek new treatments for cancer and other diseases based on epigenetics and chromatin biology. Read More
SAN FRANCISCO – Although most of the biotech world is starting the week with a J.P. Morgan Healthcare Conference hangover, it's business as usual for the redoubtable Steve Burrill, whose life sciences venture firm, Burrill & Co., recently added Capital Fund IV to its portfolio. Read More
WASHINGTON – In yet another signal that it's seriously considering drugmakers' use of social media, the FDA plans to survey health care professionals on the impact direct-to-consumer (DTC) drug promotion, whether online or in traditional media, has on their practice. Read More
BioWorld's offices were closed Monday, Jan. 16, in observance of the Martin Luther King Day holiday in the U.S. No issues were published that day. Read More
• CrystalGenomics Inc., of Pangyo, South Korea, raised KRW3 billion (US$2.6 million) through a private placement to the Korea Seoul Life Science Fund. Read More
• Seattle Genetics Inc., of Bothell, Wash., updated its prescribing information for Adcetris (brentuximab vedotin) to include a boxed warning regarding JC virus infection leading to progressive multifocal leudoencephalopathy and death. Read More
• If it can raise enough capital in the near term, Omni Bio Pharmaceutical Inc., of Denver, said it plans to begin two new clinical trials to test the efficacy of alpha-1 antitrypsin as a treatment for Type I diabetes and graft-vs.-host disease (GVHD). Read More
Apicomplexan parasites – a group that includes both the malaria and the toxoplasmosis parasite – use organelles called micronemes to get themselves into and out of the host cells where they replicate. Read More
